Oncology News | pharmaphorum

News

Pfizer's Tukysa greenlit for earlier use in breast cancer

Pfizer gets FDA approval for maintenance use of its oral HER2 inhibitor Tukysa in breast cancer, which it hopes will unlock renewed sales growth.

News

MSD ordered to pull injectable Keytruda from sale in Europe

MSD has been rocked by a court judgment ordering it to stop making and selling subcutaneous Keytruda in eight European markets.

News

Adecto, Aviceda wind down, as Caribou seeks options

There may be a fairly buoyant operating environment for biotechs in the US, but Adecto and Aviceda are winding down, while Caribou is in peril.

News

Lilly's BTK drug Jaypirca joins first-line options in US

Lilly's noncovalent BTK inhibitor Jaypirca has been cleared by the FDA for its first frontline indication, but will it be reserved for later-line use?

News

Woman undergoes a mammogram with female HCP assisting

Everlywell rolls out Clairity AI for breast cancer in US

Digital health firm Everlywell is rolling out a Clairity AI, which can assess the risk of developing breast cancer from a mammogram, across the US.

News

AZ takes stake in Summit Therapeutics in $2bn deal

AstraZeneca has taken a roughly 10% stake in Summit and signed a deal to test CLDN18.2-targeting sone-ve with PD-1xVEGF bispecific ivonescimab.

Pfizer's Tukysa greenlit for earlier use in breast cancer

MSD ordered to pull injectable Keytruda from sale in Europe

Adecto, Aviceda wind down, as Caribou seeks options

Lilly's BTK drug Jaypirca joins first-line options in US

Everlywell rolls out Clairity AI for breast cancer in US

AZ takes stake in Summit Therapeutics in $2bn deal

Lilly partners with Hims & Hers on obesity drug sales

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks